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a b s t r a c t
Migraine is a chronic, recurrent disorder, characterized by attacks of severe pain, affecting
around 1% of adult population. Many studies suggest, that trigeminovascular system plays a
key role in pathogenesis of migraine and other primary headaches. Calcitonin gene-related
peptide (CGRP) is an endogenous substance, which is regarded a key mediator released from
trigeminovascular system after stimulation of sensory nerve endings, responsible for
dilatation of peripheral vessels and sensory transmission. CGRP is and extensively studied
peptide as one of the most promising targets in migraine drug research. In the article we
focus on the role of CGRP in the pathophysiology of migraine and present current data on
CGRP antagonists and CGRP monoclonal antibodies.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Migraine is a frequent and disabling disorder with notable
socioeconomic impact. Its 1-year prevalence is estimated 11%
in USA and Western Europe. Chronic migraine (deﬁned as at
least 15 attacks per month for a minimum of three consecutive
months) affects about 4% of general population. According to
the WHO, the total annual cost of all headaches was recently
estimated at 155 billion Euros. Moreover, in the European
Union alone 190 million work-days are lost every year because
of migraine. It is estimated that migraines affect around one in
six women and one in twelve men, and are the most expensive* Corresponding author at: Department of Experimental and Clinical P
Warsaw, Poland. Tel.: +48 22 1166160; fax: +48 22 1166160.
E-mail address: ebalkowiec@wum.edu.pl (E. Bałkowiec-Iskra).
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0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Sbrain disorder with respect to associated costs to the society in
the EU and United States [13].
Although pathophysiology of migraine is still under
evaluation, many data indicate crucial role of CGRP.
CGRP is a 37 amino acid neuropeptide, which was identiﬁed
in the early 1980s as a member of the calcitonin family of
peptides [31,33]. It exists in two forms – CGRPa and CGRPb.
CGRPa is predominantly expressed in the peripheral nervous
system (PNS), CGRPb – in the enteric sensory system, in the gut
and in the pituitary gland [32]. Both forms are encoded by
separate genes. Primary neurons express more CGRPa than
CGRPb. In the PNS, CGRPa is present in trigeminal ganglia
neurons and dorsal horn cells, where it is stored withharmacology, Medical University of Warsaw, Banacha 1b, 02-091
abetically.
p. z o.o. All rights reserved.
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(in motor neurons). It is expressed in both unmyelinated C-
ﬁbers and thinly myelinated Ad ﬁbers, which innervate inter
alia epidermidis, skeletal muscles and enteric system. In the
central nervous system (CNS), CGRP was found in structures
critical for migraine pathology, such as hypothalamus, super-
ior and inferior colliculi, brainstem, trigeminal complex and
cerebellum [38]. Many studies suggest that CGRP may serve as
a link between the CNS and the PNS in the pathophysiology of
migraine [17].
CGRP receptor, cloned in 1991, belongs to the G protein-
coupled receptor superfamily. It is a heterotrimer that
contains seven transmembrane domains. It is composed of
a calcitonin receptor-like receptor (CLR), a receptor component
protein (RCP) and the receptor activity-modifying protein 1
(RAMP1) [22]. Binding of CGRP results in activation of cyclic
adenosine monophosphate (cAMP)-signaling pathway, caus-
ing raise in cAMP levels [12]. Second type – CGRP2, which was
postulated to be CGRP receptor, is not ofﬁcially recognized by
IUPHAR and is suggested to function as amylin and adreno-
medullin receptor [15].
CGRP exerts a variety of biological effects, such as
chronotropic and inotropic actions in the heart, relaxation
of urinary smooth muscle and the dilatation of arterial vessels,
which may lead to profound hypotension. CGRP causes
vascular relaxation by an endothelium and nitric oxide –
independent pathways. Activity of CGRP on venous vessels is
poorly documented. Intracranial vessels (dural and cerebral)
are supplied by thin CGRP-containing nerve ﬁbers, which
originate in the trigeminal ganglion [36].
Data show, that CGRP levels are elevated during migraine
attacks and cluster headaches in saliva and jugular venous
blood [14]. Moreover, also between attacks venous levels of
CGRP have been shown higher in migraineurs, comparing to
healthy control. Intravenous infusion of CGRP evokes mi-
graine-like headache (in addition to moderate cardiovascular
effects) in patients suffering from migraine [21]. Stimulation of
trigeminal ganglion and sensory nerves located around
intracranial vessels in humans resulted in release of CGRP,
unilateral blood ﬂow increase and ipsilateral facial ﬂushing [9].
During migraine attacks with or without aura there were no
changes in the concentration of neuropeptide Y, vasoactive
intestinal peptide, substance P. In cranial venous outﬂow,
however, marked increase in CGRP concentration was ob-
served [14]. It is postulated, that pulsating pain during
headache phase of migraine attack depends on the vasodila-
tation of intra and extra cranial arteries, which may be
mediated by CGRP [3]. Recent data demonstrated that blockade
of CGRP action can prevent or abort migraine.
2. Role of trigeminovascular system and CGRP
in pathophysiology of migraine
Trigeminovascular system (TVS) is composed of trigeminal
afferents (which cell bodies lie in the trigeminal ganglion),
their central projections and blood vessels. Fibers, which
conduct pain signals to the brain belong mainly to A delta and
C-types nociceptive ﬁbers [27]. Afferent sensory branches of
trigeminocervical nerves innervate pain-sensitive intracranialstructures, such as meningeal arteries, venous sinuses and
dura mater [26]. On the second nociceptive neurons, which are
located within the trigeminocervical complex, central projec-
tions of the trigeminocervical neurons terminate [2]. Third
order neurons are located in thalamic nuclei (mainly within
ventralposteromedial nucleus), nociceptive neurons from
trigeminocervial complex terminate on them. Thalamic
neurons project to primary somatosensory cortex, insular
cortex, limbic structures and hypothalamus. This projections
are responsible e.g. for conscious perception of the pain [30].
Activation of the brainstem was demonstrated in positron
emission tomography (PET) studies during a spontaneous
migraine attack [1]. Prior to pain onset brainstem, dorsolateral
pons, periaqueductal gray matter and hypothalamus are
active [24].
The key role in migraine headache plays sensitization of
TVS. The exact nature of triggering stimuli responsible for its
activation is still unclear. One of the leading theories proposes
that TVS activation is secondary to cortical spreading
depolarization, the other describes, that migraine is a primary
disorder during which TCC is activated episodically. TVS
sensitization and overactivation is accompanied by release of
vasoactive mediators (mainly CGRP) from activated perivas-
cular nociceptive afferents, which leads to mast cell degran-
ulation and neurogenic inﬂammation in dura matter.
Moreover, activation of parasymphathetic nerve endings
located around dural blood vessels followed by release of
acetylocholine, NO and vasoactive intestinal peptide cause
vasodilatation. Characteristic features of migraine, such as
pulsatile, throbbing headache and cutaneous alodynia, muscle
tenderness, photophobia also result from sensitization of
perivascular stimuli and higher order neurons, respectively
[11].
The trigeminovascular system is involved both in cranial
sensory functions and, with antidromic release of CGRP, in a
vasodilatation [10]. This supports hypothesis that patho-
physiology of migraine involves both altered sensory
perception of non-noxious stimuli and altered trigemino-
vascular activation. In both these processes CGRP plays
crucial role – peripherally by mediating vasodilatation via
smooth muscle cell receptors and centrally by mediating the
transmission of pain in the brainstem and second or third-
order neurons [37].
CGRP is present in nerve cell bodies of more than 40% of the
neurons in the trigeminal ganglion [9]. It is also present at
trigeminal nerve endings, in ascending second order neurons
and glia. In animal models of migraine CGRP concentration is
increased in trigeminal ganglion [20]. CGRP is released at
trigeminal nerve endings in the meninges following the
activation of the trigeminal system. This causes vasodilatation
and activation of sensory trigeminal pain neurons, innervating
dura mater and intracranial blood vessels. Studies show that
symptoms of migraine, such as aura, allodynia and photopho-
bia are mediated by CGRP and can be alleviated by blocking its
function [40].
CGRP plays crucial role in both initiation and progression of
migraine and primary headaches. Thus, blockade of CGRP
action should result in symptoms decrease. Various strategies
have been employed to affect CGRP function. This includes
small molecules or monoclonal antibodies, which compete for
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and CLR. Monoclonal antibodies, neutralizing free CGRP are
also under clinical evaluation.
3. CGRP receptor antagonists
3.1. Olcegepant (BIBN4096)
Olcegepant was the ﬁrst CGRP receptor antagonist devel-
oped. It binds speciﬁcally to RAMP1 extracellular region and
thus competes for the binding site of the endogenous CGRP
[23]. It was shown clinically effective when administered
intravenously during acute migraine attack. The effect was
observed 30 min after administration with improvement
over a few hours. Doses ranged from 0.25 to 10 mg, pooled
response rate achieved 60%. About one third of patients
treated suffered from side effects, mainly paresthesias. No
intrinsic cardiovascular effects were reported [28]. Although
the results with olcegepant were encouraging, drug was
effective only after intravenous administration due to its
poor oral bioavailability. Moreover, it had poor penetration
across the blood-brain barrier (BBB) and although effectively
blocked the CGRP-induced temporal artery dilatation, it did
not modify the tone of cerebral vessels [29]. As migraine is
treated primarily on an outpatient basis, olcegepant studies
were discontinued because of difﬁculties in developing an
oral formulation.
3.2. Telcagepant (MK-0974)
Telcagepant was the ﬁrst orally available CGRP receptor
antagonist. In pharmacokinetic studies it was rapidly
absorbed, with Tmax of 1.5 h and terminal half-life 6 h. Steady
state was achieved in 3–4 days after twice daily dosing,
separated by 2 h [6]. In Phase 3 clinical trial, with zolmitriptan
5 mg as an active comparator and 1380 patients being
randomized, telcagepant 300 mg had similar 2-h efﬁcacy to
zolmitriptan and superior to telcagepant, 150 mg. Both doses
of telcagepant had superior efﬁcacy but similar tolerability to
placebo [18]. Moreover, it was effective in treating migraine
associated symptoms, such as photophobia, phonophobia and
nausea. However, some patients treated in Phase 2 twice daily
showed elevated transaminases after more than 2 weeks of
treatment. Such hepatic signs were not observed in acute
intermittent therapy, which suggest, that the risk of hepato-
toxicity may be dose- and time-dependent. Thus, concerns
regarding liver toxicity caused discontinuation of telcagepant
development.
3.3. MK-3207
In clinical trials it was signiﬁcantly more effective in pain relief
than placebo. However, liver toxicity concerns caused discon-
tinuation of the drug [16].
3.4. BI 44370
It was shown more effective than both placebo and eletriptan
in Phase 2 study. Tolerability was good, adverse events werenoted in 1.4–9.4% of treated patients (depending on dose).
However, no further trials have been published [7].
3.5. BMS-846372/927711
Discovered in 2012, showed efﬁcacy similar to sumatriptan in
Phase 2b study. It was superior to placebo, no signiﬁcant
adverse effects were described. However, only one single
attack was treated in each patient involved, so further studies
are needed to conﬁrm its tolerability and safety proﬁle [25].
3.6. MK-1602
The compound is currently under evaluation [19]. No data on
its efﬁcacy or safety has been published yet.
Liver toxicity observed during chronic continuous admin-
istration of CGRP antagonists raised concerns about its safe
use in the clinics. As migraine is a chronic disease, which
should be treated without hospitalization, drugs must be
effective in oral for and safe when used chronically. Out of six
available CGRP antagonists, three could not fulﬁll both of this
requirements, remaining three are under evaluation. An
alternative approach to the treatment of migraine by affecting
CGRP function is use of monoclonal antibodies against the
CGRP ligand and CGRP receptor.
3.7. CGRP Monoclonal antibodies (mAbs)
CGRP mABs are being developed particularly for migraine
prophylaxis. They have the slower onset of action and much
longer half-life comparing with CGRP receptor antagonists.
Moreover, they might be administered once a month or even
less frequently, while currently available migraine preven-
tive medications are recommended orally one to three times
daily [35]. Although mAbs are macromolecules, which
potentially are incapable of crossing the BBB, it is possible,
that during migraine attack, BBB is more permeable to allow
its central action. mABs are characterized by high selectivi-
ty, which allows avoiding toxicities, reported previously
for CGRP antagonists. However, as CGRP has many physio-
logical actions in the organism, some concerns, mainly
cardiovascular of CGRP inhibitions use, raised. As CGRP is
a potent vasodilatator, risk of medication-induced hyper-
tension, counterbalancing the vasodilatatory effect of
anti-hypertensive drugs, inhibition of stress induced vaso-
dilatation and inhibition of cardio-protective mechanisms
during ischemia might be potential risks for patients treated
with CGRP mAbs [5]. Moreover, infusion and administration
immunological reactions are other potential undesirable
effects.
Several studies have been carried of – three mAbs directly
bind to and neutralize excessive CGRP, that is released at
perivascular trigeminal sensory nerve ﬁbers and thus prevent
the binding of CGRP to its receptor. This includes LY2951742
(fully humanized mAB), ALD-403 (a genetically engineered
humanized anti-CGRP antibody) and LBR-101 (also known as
TEV-48125). AMG 334 is a humanized mAb against CGRP
receptor, which blocks CGRP signaling [4]. All the four
antibodies are indicated in the treatment of episodic and
chronic migraine.
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This is a humanized antibody, which has been shown to
prevent the binding of CGRP to its receptor. Administered
subcutaneously has been shown to prevent dermal blood ﬂow
increase induced by capsaicin in healthy human subjects, rats
and non-human primates [34]. Efﬁcacy of LY2951742 was
studied in a phase 2a double-blinded placebo controlled trial in
episodic migraine. The compound, administered subcutane-
ously every alternate week for 12 weeks showed signiﬁcant
decrease in headache days (62.5% vs. 42.3 in placebo group) at
week 12. Adverse events (including pain at injection site,
erythema, upper respiratory tract infections and abdominal
pain) were more frequent in the treatment than in the placebo
group. However, no serious adverse events, attributed to
treatment, occurred [8].
According to https://www.clinicaltrials.gov two studies are
currently recruiting patients with chronic and episodic cluster
headaches.
3.9. ALD 403
ALD 403 is a humanized antibody, produced using yeast, not
mammalian cells. Half life of the compound is approximately
32 days for the dose 1000 mg. Two different formulations,
administered subcutaneously and intravenously were tested
in Phase 1 placebo controlled study. In phase 2a study, 163
participants with episodic migraine received a single 1000 mg
i.v. dose and were followed for 6 months. Decrease in the
number of migraine days (5.6 vs. 4.6 in placebo group, p = 0.03)
in the second month after treatment relative to number before
treatment was shown. Adverse effects were experienced by
57% of patients from ALD403 group and 52% of patients from
placebo group. Most frequently upper respiratory tract infec-
tions, urinary tract infections, fatigue, back pain, arthralgia,
nausea and vomiting were reported [5]. According to https://
www.clinicaltrials.gov one study: ‘‘A Multicenter Assessment
of ALD 403 in Chronic Migraine’’ is currently recruiting
patients. The primary outcome measure of the study is
change in migraine days from baseline to week 12, estimated
enrollment is 600 patients.
3.10. AMG 334
It is the anti-CGRP antibody that targets the CGRP receptor
complex, not the free ligand. Its safety and effectiveness is
studied in episodic and chronic migraine. It is administered
subcutaneously, once a month. In phase I study a statistically
signiﬁcant reduction in monthly headache days were observed
at week 12 in patients treated with dose of 70 mg [40].
According to https://www.clinicaltrials.gov two studies are
recruiting patients with chronic migraine, further two will
start July and August 2015, respectively. All of the studies will
assess the compound in migraine prevention, three of the
studies will be placebo-controlled.
3.11. LBR-101 (TEV-48125)
It was developed for episodic and chronic migraine from the
start. Two studies conducted in monkeys showed, that theagent do not affect cardiovascular and hemodynamic param-
eters [39]. Similarly, no cardiological side effects were observed
up to 3 months post dose in 31 subjects. Pharmacokinetic
studies showed, that the half-life is 44–48 days. There are no
on-going studies on LBR-101, registered on https://www.
clinicaltrials.gov.
4. Conclusion
CGRP is the important neuropeptide in migraine pathophysi-
ology. It seems to mediate not only pain, but also photophobia,
aura and allodynia observed in patients. Thus, therapeutical
strategies targeting CGRP function seem to be promising.
Route of administration and hepatotoxicity limited use of
CGRP antagonists, however, effectiveness and safety proﬁle of
CGRP monoclonal antibodies seem favorable especially for
chronic administration in preventive migraine treatment.
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